April 2026 in “Boletín Médico Del Hospital Infantil de México (English Edition)” Most kids with alopecia areata have other health issues, often allergies or skin conditions.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
4 citations
,
July 2025 in “Frontiers in Immunology” Early intervention with JAK inhibitors may prevent alopecia areata progression.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
2 citations
,
October 2024 in “Dermatology and Therapy” Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
2 citations
,
October 2023 in “Frontiers in Immunology” People with rheumatoid arthritis have a higher risk of developing alopecia areata.
1 citations
,
March 2025 in “Frontiers in Physiology” Methotrexate, resveratrol, and curcumin may help treat alopecia areata by targeting immune cells.
1 citations
,
January 2025 in “Frontiers in Immunology” Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
March 2026 in “Frontiers in Medicine” Diffuse unpatterned alopecia can affect donor areas, but treatment with finasteride and minoxidil can improve hair density.
February 2026 in “Frontiers in Public Health” Alopecia areata is increasing globally, with disparities needing better prevention and support.
November 2025 in “Frontiers in Immunology” SQSTM1 gene issues may increase the risk of alopecia areata.
November 2025 in “Frontiers in Medicine” Baseline severity and relapse history affect alopecia areata treatment and recurrence.
November 2025 in “Frontiers in Medicine” The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.
August 2025 in “Frontiers in Immunology” Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
January 2026 in “Frontiers in Medicine” Alopecia areata in Taiwan has a high disease burden and needs better research and diagnostic criteria.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
August 2025 in “Frontiers in Immunology” People with alopecia areata have a higher risk of heart disease.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
October 2023 in “Revista Medicina Cutánea Ibero-Latino-Americana” Alopecia areata often appears on the scalp and is linked to various health issues, needing thorough evaluation.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
67 citations
,
March 2021 in “Dermatology and Therapy” Alopecia areata greatly harms quality of life, causing emotional and social issues.
24 citations
,
February 2021 in “Dermatology and Therapy” COVID-19 increased alopecia areata relapses due to inflammation and stress.
22 citations
,
November 2021 in “Dermatology and Therapy” The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
17 citations
,
January 2022 in “Annals of Dermatology” Severe pediatric alopecia areata worsens quality of life for patients and families.
14 citations
,
January 2017 in “Annals of Dermatology” Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.